SCHEMBL26426348

SCHEMBL26426348

CC(C)(C)OC(=O)N1CCN(C(=O)OC(C)(C)C)C2(CCC2=O)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 1/20 0.42
GRIN2C Q14957 1/20 0.42
DDB1 Q16531 2/20 0.40
CRBN Q96SW2 2/20 0.40
USP2 O75604 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CYP11B2 P19099 1/20 0.38
USP30 Q70CQ3 1/20 0.38
EPHX2 P34913 1/20 0.36
CKS1B P61024 1/20 0.36
SKP1 P63208 1/20 0.36
SKP2 Q13309 1/20 0.36
ACACB O00763 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ESR2 Q92731 1/20 0.36
MAPT P10636 2/20 0.35
KDM4E B2RXH2 1/20 0.35
THRB P10828 1/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26426355 0.84 GRIN2B (0.42) GRIN2BGRIN2CDDB1CRBNCYP11B2
SCHEMBL19839394 0.80 DDB1 (0.39) GRIN2BGRIN2CDDB1CRBNUSP2
SCHEMBL25262354 0.77 GRIN2B (0.48) GRIN2BGRIN2CDDB1CRBNUSP2
SCHEMBL30832426 0.77 GRIN2B (0.48) GRIN2BGRIN2CDDB1CRBNUSP2
SCHEMBL31171462 0.77 DDB1 (0.43) DDB1CRBNUSP2SMN1; SMN2CYP11B2
SCHEMBL31566998 0.75 USP30 (0.50) DDB1CRBNUSP2SMN1; SMN2CYP11B2
SCHEMBL20521260 0.75 USP30 (0.50) DDB1CRBNUSP2SMN1; SMN2CYP11B2
SCHEMBL31566493 0.75 USP30 (0.50) DDB1CRBNUSP2SMN1; SMN2CYP11B2
SCHEMBL30832396 0.75 GRIN2B (0.50) GRIN2BGRIN2CDDB1CRBNUSP2
SCHEMBL26378535 0.75 GRIN2B (0.53) GRIN2BGRIN2CDDB1CRBNUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230131402-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF APTINYX INC (US) 2023-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230131402-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN3A GRIN2B 5/4885GRIN2C 4/4885DDB1 3406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.